ARTICLE | Company News
Merck, Yamasa deal
July 30, 2012 7:00 AM UTC
Yamasa granted Merck exclusive, worldwide rights to EFdA, a preclinical nucleoside reverse transcriptase inhibitor. Yamasa will receive an undisclosed upfront fee and is eligible for milestones. The c...